论文部分内容阅读
目的探讨哌拉西林/舒巴坦联合盐酸氨溴索治疗2型糖尿病肺部感染患者的疗效,以提高临床治疗水平。方法 2011年6月-2014年6月98例2型糖尿病肺部感染患者随机分为观察组和对照组,每组各49例,所有患者均注射胰岛素控制血糖和常规对症治疗,并采用抗菌药物哌拉西林/舒巴坦静脉滴注治疗,观察组在此基础上给予盐酸氨溴索片治疗,对照组在此基础上给予盐酸溴己新片治疗,对比两组患者的治疗效果、症状改善起效时间和不良反应发生率。结果观察组患者治疗总有效率为91.8%,显著优于对照组的69.4%,差异有统计学意义(P<0.01);观察组患者的发热、咳嗽、咳痰症状改善时间及住院时间显著低于对照组,差异有统计学意义(P<0.01);患者不良反应发生率观察组为10.2%、对照组为12.2%,差异无统计学意义。结论哌拉西林/舒巴坦联合盐酸氨溴索治疗2型糖尿病肺部感染,能提升治疗有效率、缩短症状改善时间,且不良反应小,值得临床推广。
Objective To investigate the curative effect of piperacillin / sulbactam combined with ambroxol hydrochloride in patients with type 2 diabetes mellitus with pulmonary infection and to improve the clinical treatment level. Methods From June 2011 to June 2014, 98 patients with type 2 diabetes mellitus with pulmonary infection were randomly divided into observation group and control group, 49 cases in each group. All patients were injected with insulin to control blood sugar and conventional symptomatic treatment. Antibiotics Piperacillin / sulbactam intravenous infusion, the observation group on this basis to give ambroxol hydrochloride tablets, the control group on the basis of bromhexine hydrochloride tablets treatment, the two groups were compared the therapeutic effect, the symptoms improved from Effective time and adverse reaction rate. Results The total effective rate of observation group was 91.8%, which was significantly better than that of the control group (69.4%), the difference was statistically significant (P <0.01). The observation group had significantly lower fever, cough, expectoration time and hospital stay In the control group, the difference was statistically significant (P <0.01). The incidence of adverse reactions in the observation group was 10.2% in the observation group and 12.2% in the control group, with no significant difference. Conclusion Piperacillin / sulbactam combined with ambroxol hydrochloride in the treatment of type 2 diabetic pulmonary infection can improve the treatment efficiency, shorten the time to symptom improvement, and the adverse reaction is small, worthy of clinical promotion.